L. E. Korotaeva
Research Subjects
L. E. Korotaeva has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Tatsiana V. Mokhort
Belarusian State Medical University
2 shared publications - Volha Vasilkova
Gomel State Medical University
2 shared publications - Ya. A. Borovets
Gomel State Medical University
2 shared publications - Yuliya I. Yarets
Republican Research Center for Radiation Medicine and Human Ecology
2 shared publications - E. P. Naumenko
The Republican Research Center for Radiation Medicine and Human Ecology
1 shared publication - Elena Edgarovna Naumenko
Pyatigorsk State University
1 shared publication
Latest Publications
- Open Access
- 30 June 2021
- Published by Gomel State Medical University in Health and Ecology Issues
- No. 2,p. 79-85
Diagnostic value of cystatin C for the early diagnosis of diabetic nephropathy
Objective:to assess the clinical significance of cystatin C in the early diagnosis of diabetic nephropathy.Materials and methods.We examined 449 patients with type 1 and type 2 diabetes mellitusolder than 25 years. The laboratory examination of the patients included the measurement of cystatin, creatinine in the blood serum, GFR calculation according to the CKD-EPI equation, and the determination of albuminuria levels.Results.The role of cystatin C as a reliable marker of diabetic nephropathy has been demonstrated: the level of cystatin C ≥ 0.72 mg/L with sensitivity of 90.8 %, specificity of 88.9 %, was associated with a decline of renal function in the diabetic patients (ROC AUC = 0.951).Conclusion.The determination of the level of cystatin C, alone or in conjunction with creatinine, will help to more accurately diagnose GFR and assess the risk of mortality and renal complications in patients with diabetes mellitus.
- 30 June 2021
- Published by Gomel State Medical University in Health and Ecology Issues
- No. 2,p. 79-85
Open AccessDiagnostic value of cystatin C for the early diagnosis of diabetic nephropathy
Objective:to assess the clinical significance of cystatin C in the early diagnosis of diabetic nephropathy.Materials and methods.We examined 449 patients with type 1 and type 2 diabetes mellitusolder than 25 years. The laboratory examination of the patients included the measurement of cystatin, creatinine in the blood serum, GFR calculation according to the CKD-EPI equation, and the determination of albuminuria levels.Results.The role of cystatin C as a reliable marker of diabetic nephropathy has been demonstrated: the level of cystatin C ≥ 0.72 mg/L with sensitivity of 90.8 %, specificity of 88.9 %, was associated with a decline of renal function in the diabetic patients (ROC AUC = 0.951).Conclusion.The determination of the level of cystatin C, alone or in conjunction with creatinine, will help to more accurately diagnose GFR and assess the risk of mortality and renal complications in patients with diabetes mellitus.
- Open Access
- 1 January 2020
- Published by Scientia Publishing House LTD in Juvenis scientia
- Vol. 6 (2) , 36-43
EVALUATION OF THE LEVELS OF FIBROBLAST GROWTH FACTOR (FGF-23) AND INFLAMMATION MARKERS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND DIFFERENT STAGES OF CHRONIC KIDNEY DISEASE
Recently, inflammatory and regulatory mechanisms that are involved in the onset and progression of angiopathies in diabetes mellitus (DM), including diabetic kidney disease (DKD), have been studied. In this study, we assessed the levels of fibroblast growth factor-23 (FGF-23) and inflammatory markers in patients with type 2 DM and different stages of chronic kidney disease (CKD). We investigated 64 patients with type 2 DM aged 34-84 years. The results showed significant changes in the levels of FGF-23, tumour necrosis factor alpha (TNF-alpha), C-reactive protein (CRP), high-sensitivity C-reactive protein (hsCRP), and interleukin-6 (IL-6) with the progression of CKD in patients with type 2 diabetes. Multiple regression analysis demonstrated the presence of an independent interconnection between serum levels of FGF-23 and creatinine.
- 1 January 2020
- Published by Scientia Publishing House LTD in Juvenis scientia
- Vol. 6 (2) , 36-43
Open AccessEVALUATION OF THE LEVELS OF FIBROBLAST GROWTH FACTOR (FGF-23) AND INFLAMMATION MARKERS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS AND DIFFERENT STAGES OF CHRONIC KIDNEY DISEASE
Recently, inflammatory and regulatory mechanisms that are involved in the onset and progression of angiopathies in diabetes mellitus (DM), including diabetic kidney disease (DKD), have been studied. In this study, we assessed the levels of fibroblast growth factor-23 (FGF-23) and inflammatory markers in patients with type 2 DM and different stages of chronic kidney disease (CKD). We investigated 64 patients with type 2 DM aged 34-84 years. The results showed significant changes in the levels of FGF-23, tumour necrosis factor alpha (TNF-alpha), C-reactive protein (CRP), high-sensitivity C-reactive protein (hsCRP), and interleukin-6 (IL-6) with the progression of CKD in patients with type 2 diabetes. Multiple regression analysis demonstrated the presence of an independent interconnection between serum levels of FGF-23 and creatinine.